An AI-powered digital twin platform that integrates plant primary and secondary metabolomics, proteomics, and literature-derived data to predict the mode of action and molecular targets of novel phytoeffectors such as herbicides, fungicides, and stress compounds. Built on validated expertise in plant metabolism and a proven methodology previously applied to anticancer drug discovery, the platform enables faster, standardized screening of small-molecule crop protection candidates.
This solution offers a standardized omics-based digital twin for plants that predicts how small-molecule phytoeffectors influence plant metabolism and identifies their likely mode of action and protein targets. By combining plant primary and secondary metabolomics, proteomics, and literature-based smart data analysis within a metabolic network model, the platform provides a holistic view of how candidate compounds interact with crop plants. The approach is designed to accelerate the discovery and characterization of new crop protection agents, including herbicides and fungicides, by replacing slow, hypothesis-driven screening with pattern-based AI analysis.
The concept builds directly on a previously developed methodology and machine learning tool used to characterize the effects of anticancer drugs on human cancer cells, now extended and adapted to plant systems. The result is a decision-support tool for researchers and agritech companies seeking to understand compound behavior, optimize candidate selection, and reduce development risk.
Core capabilities:
Key features:
The underlying expertise in plant secondary metabolomics and phytoeffector response analysis is well established, with decades of experience in studying plant metabolism under stress and small-molecule influence. A closely related methodology and machine learning tool has already been developed for anticancer drug mode-of-action discovery and is currently under submission. To reach full digital twin readiness, the platform requires additional standardization of targeted plant primary metabolome measurements, integration of proteome data, and incorporation of literature-derived smart data analysis. The platform is therefore positioned at an advanced research stage, ready for collaborative development and validation with industry partners.
Leibniz University Hannover is a large, comprehensive public research university with about 25,000 students, 5,000 staff, and a broad academic profile. Its infrastructure spans Hannover and Garbsen, including co-located facilities where researchers work with external partners. Medical Park Hannover places the university near medical and engineering companies, Hannover Medical School, and other research institutions; uni transfer helps companies access researchers, expertise, equipment, and collaboration pathways. Funding comes from the German Research Foundation, federal government and Lower Saxony programmes, the Volkswagen Foundation, and European Union programmes, complemented by patenting, licensing, and start-up support.